Clinical radioimmunotherapy--the role of radiobiology. (Q37953785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Clinical radioimmunotherapy--the role of radiobiology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Nicolas Chouin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Guillaume Cartron

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Isabelle Navarro-Teulon

2

object named as

Isabelle Navarro-Teulon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Jean-Pierre Pouget

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

André Pèlegrin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

David Azria

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

8 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

720-734

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

New insights on cell death from radiation exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiation-induced cell signaling: inside-out and outside-in

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiation-induced cell death mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Apoptosis-modulating agents in combination with radiotherapy-current status and outlook

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Antibody-targeted radiation cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

General aspects of the cellular response to low- and high-LET radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Molecular and cellular radiobiological effects of Auger emitting radionuclides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Targeting the nucleus: an overview of Auger-electron radionuclide therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Rationales, evidence, and design considerations for fractionated radioimmunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiobiological aspects of low dose rates in radioimmunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Dose-rate effects in external beam radiotherapy redux

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Targeted radiotherapy: microgray doses and the bystander effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiation-induced bystander signalling in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy in follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy of lymphoma: Bexxar and Zevalin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

131I-tositumomab therapy as initial treatment for follicular lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunoconjugates in acute leukemia treatment: the future is radiant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Review of low-dose-rate radiobiology for clinicians

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Cancer radioimmunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Targeted radiotherapy of brain tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Towards translation of 212Pb as a clinical therapeutic; getting the lead in!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Consolidation for ovarian cancer in remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Antibody-based vascular tumor targeting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Systemic targeted radionuclide therapy: potential new areas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Combining radiotherapy and immunotherapy: a revived partnership

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Optimization of radioimmunotherapy interactions with hyperthermia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy-based conditioning regimens for stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.160

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma

31 March 2020

1 reference

12 December 2020

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer

1 reference

12 December 2020

Current status and perspectives in alpha radioimmunotherapy.

1 reference

12 December 2020

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

1 reference

12 December 2020

Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.

1 reference

12 December 2020

Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.

1 reference

12 December 2020

The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A

1 reference

12 December 2020

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

1 reference

12 December 2020

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG

1 reference

12 December 2020

From imaging to dosimetry and biological effects.

1 reference

12 December 2020

Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model

1 reference

12 December 2020

Quantitative comparison of radiolabeled antibody therapy and external beam radiotherapy in the treatment of human glioma xenografts

1 reference

12 December 2020

Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.

1 reference

12 December 2020

Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR

1 reference

12 December 2020

Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice.

1 reference

12 December 2020

Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody

1 reference

12 December 2020

Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer

1 reference

12 December 2020

Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer

1 reference

12 December 2020

A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.

1 reference

12 December 2020

Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.

1 reference

12 December 2020

Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.

1 reference

12 December 2020

Implications of nonuniform tumor doses for radioimmunotherapy.

1 reference

12 December 2020

Dosimetry in nuclear medicine therapy: radiobiology application and results

1 reference

12 December 2020

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

12 December 2020

Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts

1 reference

12 December 2020

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

1 reference

12 December 2020

Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?

1 reference

12 December 2020

Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry

1 reference

12 December 2020

Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

1 reference

12 December 2020

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial

1 reference

12 December 2020

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

1 reference

12 December 2020

Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.

1 reference

12 December 2020

Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.

1 reference

12 December 2020

Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer

1 reference

12 December 2020

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer

1 reference

12 December 2020

Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial

1 reference

12 December 2020

Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam

1 reference

12 December 2020

Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer

1 reference

12 December 2020

Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation

1 reference

12 December 2020

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma

1 reference

12 December 2020

Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.

1 reference

12 December 2020

Overview of studies on experimental radioimmunotherapy.

1 reference

12 December 2020

10.1038/NRCLINONC.2011.160

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064461%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference